MacroGenics, Inc. (NASDAQ: MGNX) Stock Information | RedChip
Image

ASK REDCHAT ANYTHING ABOUT MACROGENICS, INC.

MacroGenics, Inc. (NASDAQ: MGNX)
Listen to this Section


$4.07
-0.1850 ( -4.35% ) 189.3K

Macrogenics Inc is a biotechnology company focused on discovering and developing antibody-based therapeutics for the treatment of cancer. Its product includes MARGENZA, which is for the treatment of adult patients with metastatic HER2-positive breast cancer. It's a pipeline of product candidates designed to target either various tumor-associated antigens or immune checkpoint molecules. Its pipeline MGC018 (B7-H3), Lorigerlimab (PD-1 × CTLA-4), Tebotelimab (PD-1 × LAG-3), MGD024 (CD123 × CD3), IMGC936 (ADAM9), Enoblituzumab (anti-B7-H3), Retifanlimab (PD-1), and MGD014 (HIV × CD3).

Market Data


Open $4.07
Previous Close $4.25
Volume 189.3K
Market Cap $266.97M
Day Range $4.02 - $4.30
52 Week Range $1.19 - $4.64
Shares Outstanding 63.56M
Change % -4.35%
Net Change ▼ -0.1850
Insider Ownership -0.04%
Exchange NASDAQ
SectorMiscellaneous
IndustryNone
IPO Year2013
CountryUnited States
UnderwriterIPO Intelligence Only

Insider Ownership Transactions

Total Amount Purchased: 37,500.00

Date Type Amount Purchased Purchaser
2025-08-21 Buy 50500.00 HEIDEN WILLIAM K
2024-05-23 Sale -6500.00 Chhabra Meenu
2024-05-23 Sale -6500.00 SIEGEL JAY PHILIP

SEC Filings


Form Type Description Pages Date
8-k 8K-related 14 Jun 10, 2025

Latest News


× Before browsing our site, please accept our cookies policy